Current Knowledge in Thyroid Cancer — From Bench to Bedside
In recent years, studies in the field of thyroid cancer have been performed in order to identify and verify thyroid specific biomarkers, as well as cancer-specific changes in gene expression patterns and alterations of the protein content. Furthermore, new drugs, small molecules and antibodies were...
Պահպանված է:
| Հիմնական հեղինակ: | |
|---|---|
| Ձևաչափ: | Online |
| Լեզու: | անգլերեն |
| Հրապարակվել է: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Խորագրեր: | |
| Առցանց հասանելիություն: | 23343 |
| Ցուցիչներ: |
Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!
|
| _version_ | 1869516043197612032 |
|---|---|
| author | Daniela Gabriele Grimm (Ed.) |
| author_browse | Daniela Gabriele Grimm (Ed.) |
| author_facet | Daniela Gabriele Grimm (Ed.) |
| author_sort | Daniela Gabriele Grimm (Ed.) |
| collection | Directory of Open Access Books |
| description | In recent years, studies in the field of thyroid cancer have been performed in order to identify and verify thyroid specific biomarkers, as well as cancer-specific changes in gene expression patterns and alterations of the protein content. Furthermore, new drugs, small molecules and antibodies were developed and tested in vitro and in vivo. Trials investigated the ratio between therapeutic and adverse effects. Tyrosine kinase inhibitors (TKI) have become a new therapeutic option of both differentiated thyroid cancer and medullary thyroid cancer. In the last few years, new substances for targeted systemic therapy have been approved after their efficacy was demonstrated in Phase III trials. Most of them show a moderate response. However, adverse effects are common. TKI are used in patients with advanced metastatic thyroid cancer that is radioiodine (RAI)-refractory. In this Special Issue, original studies on the pathophysiology, diagnosis, and therapy of thyroid cancer, including genetics, proteomics, metabolomics, molecular and cell biology, will be published. It will also cover reports on patients, providing novel mechanistic insights into the underlying pathogenesis or new aspects that may impact clinical therapy, and recent study results in order to review the current status of new therapy options in thyroid cancer. |
| format | Online |
| id | doab-20.500.12854ir-44417 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-444172024-04-05T12:31:54Z Current Knowledge in Thyroid Cancer — From Bench to Bedside Daniela Gabriele Grimm (Ed.) QH301-705.5 molecular biology Thyroid cancer biomarkers OMICS investigations clinical studies pathway analyses In vitro studies Tyrosine kinase inhibitors thema EDItEUR::P Mathematics and Science::PS Biology, life sciences In recent years, studies in the field of thyroid cancer have been performed in order to identify and verify thyroid specific biomarkers, as well as cancer-specific changes in gene expression patterns and alterations of the protein content. Furthermore, new drugs, small molecules and antibodies were developed and tested in vitro and in vivo. Trials investigated the ratio between therapeutic and adverse effects. Tyrosine kinase inhibitors (TKI) have become a new therapeutic option of both differentiated thyroid cancer and medullary thyroid cancer. In the last few years, new substances for targeted systemic therapy have been approved after their efficacy was demonstrated in Phase III trials. Most of them show a moderate response. However, adverse effects are common. TKI are used in patients with advanced metastatic thyroid cancer that is radioiodine (RAI)-refractory. In this Special Issue, original studies on the pathophysiology, diagnosis, and therapy of thyroid cancer, including genetics, proteomics, metabolomics, molecular and cell biology, will be published. It will also cover reports on patients, providing novel mechanistic insights into the underlying pathogenesis or new aspects that may impact clinical therapy, and recent study results in order to review the current status of new therapy options in thyroid cancer. 2021-02-11T10:53:18Z 2021-02-11T10:53:18Z 2017-08-11 11:32:17 2017 book 23343 9783038424772 9783038424765 https://directory.doabooks.org/handle/20.500.12854/44417 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International http://www.mdpi.com/books/pdfview/book/338 http://www.mdpi.com/books/pdfview/book/338 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03842-477-2 10.3390/books978-3-03842-477-2 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783038424772 9783038424765 VIII, 212 open access |
| spellingShingle | QH301-705.5 molecular biology Thyroid cancer biomarkers OMICS investigations clinical studies pathway analyses In vitro studies Tyrosine kinase inhibitors thema EDItEUR::P Mathematics and Science::PS Biology, life sciences Daniela Gabriele Grimm (Ed.) Current Knowledge in Thyroid Cancer — From Bench to Bedside |
| title | Current Knowledge in Thyroid Cancer — From Bench to Bedside |
| title_full | Current Knowledge in Thyroid Cancer — From Bench to Bedside |
| title_fullStr | Current Knowledge in Thyroid Cancer — From Bench to Bedside |
| title_full_unstemmed | Current Knowledge in Thyroid Cancer — From Bench to Bedside |
| title_short | Current Knowledge in Thyroid Cancer — From Bench to Bedside |
| title_sort | current knowledge in thyroid cancer from bench to bedside |
| topic | QH301-705.5 molecular biology Thyroid cancer biomarkers OMICS investigations clinical studies pathway analyses In vitro studies Tyrosine kinase inhibitors thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| topic_facet | QH301-705.5 molecular biology Thyroid cancer biomarkers OMICS investigations clinical studies pathway analyses In vitro studies Tyrosine kinase inhibitors thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| url | 23343 |
| work_keys_str_mv | AT danielagabrielegrimmed currentknowledgeinthyroidcancerfrombenchtobedside |